Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab

Abstract Digital health technology (DHT) tools for Parkinson’s disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab. 316 early-stage PD participants were ra...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kirsten I. Taylor, Florian Lipsmeier, Marzia A. Scelsi, Ekaterina Volkova-Volkmar, Daria Rukina, Werner Popp, Stefan Lambrecht, Judith Anzures-Cabrera, David Summers, Markus Abt, Annabelle Monnet, Timothy Kilchenmann, Jens Schjodt-Eriksen, Laurent Essioux, Thomas Kustermann, Wagner Zago, Hanno Svoboda, Tania Nikolcheva, Ronald B. Postuma, Gennaro Pagano, Michael Lindemann, PASADENA Investigators, Prasinezumab Study Group
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2025-06-01
coleção:	npj Digital Medicine
Acesso em linha:	https://doi.org/10.1038/s41746-025-01572-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!